SAT-533 From Fingersticks To Feedback: Assessing The Clinical Outcome Of CGM Implementation In A Resident-run PCP Clinic In An Underserved Community

Abstract Disclosure: K.N. Pereira: None. B. Agrawal: None. V. Mehta: None. S. Nagpaul: None. S.R. Russell: None. Introduction: Type 2 Diabetes Mellitus (T2D) affects over 38 million Americans, with 90-95% diagnosed with T2D. Persistent hyperglycemia leads to multi-organ complications. Self-monitoring of blood glucose (SMBG) has been the standard; however, Continuous Glucose Monitoring (CGM) offers real-time data, enabling proactive, individualized diabetes management. Objective: This study was aimed to evaluate the impact of CGM on glycemic control, specifically assessing HbA1c reductions among adults with T2D in a resident-run primary care clinic serving an underserved community. Methods: A retrospective chart review was conducted on a random sample of 52 patients initiated on CGM between January and December 2023. Baseline HbA1c levels prior to CGM initiation and subsequent measurements at regular intervals were noted. Outcomes were categorized as improvement (≥0.5% reduction), worsening (≥0.5% increase), or no significant change (<0.5% change). Cases of loss to follow-up or CGM discontinuation were noted. Descriptive statistics summarized patient outcomes and trends. Results: Among the 52 patients reviewed, 53.85% demonstrated HbA1c improvement, 9.6% showed worsening, and 36.55% were lost to follow-up or did not initiate CGM use. Two patients died during the study period. The majority who utilized CGM experienced meaningful glycemic control improvements. Identified barriers included device application challenges, insurance coverage issues, financial constraints, limited patient education, and logistical difficulties in obtaining devices. Discussion: CGM use in T2D patients has been associated with statistically significant HbA1c reductions compared to SMBG. Intermittent use of CGM has been found to significantly decrease calorie consumption, increase in physical activity, improve weight, improve body composition, and decrease HbA1c up to 1% in poorly controlled patients with T2D by providing immediate feedback on lifestyle factors, enhancing patient engagement and self-management. Increased time in range, reduced microvascular complications as well as hypoglycemia have been identified in CGM users. However, barriers such as cost, insurance coverage, and limited provider knowledge hinder widespread adoption. In our study, provider education improved CGM prescription rates, highlighting the need for targeted interventions to overcome these challenges. Conclusion: Implementing CGM in a resident-led clinic serving an underserved community led to significant HbA1c reductions in over half of the T2D patients. Addressing barriers related to device access, patient education, and provider training is crucial for optimizing CGM utilization and improving diabetes outcomes in similar populations. Presentation: Saturday, July 12, 2025